The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis

Rheumatology International

Volumn 33, Issue 4, 2013, Pages 965-971

  Limaye, Vidya ^a,b   Luke, Colin ^c   Tucker, Graeme ^d   Hill, Catherine ^e   Lester, Susan ^e   Blumbergs, Peter ^f   Roberts Thomson, Peter ^g  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c DEPARTMENT OF HUMAN SERVICES   (Australia)

^d Epidemiology Branch Health System Information and Performance Operations Division   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^g SA PATHOLOGY   (Australia)

Author keywords

Cancer; Dermatomyositis; Inclusion body myositis; Muscle histology; Polymyositis; Standardized incidence ratio

Indexed keywords

CREATINE KINASE; ENDOMYSIUM ANTIBODY; HLA A ANTIGEN;

ADULT; ALLELE; ARTICLE; AUSTRALIA; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COHORT ANALYSIS; COLON CANCER; CREATINE KINASE BLOOD LEVEL; DATA BASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; ELECTROMYOGRAPHY; ENDOMETRIUM CANCER; FEMALE; GENETIC PREDISPOSITION; GENETIC RISK; HLA SYSTEM; HLA TYPING; HODGKIN DISEASE; HUMAN; INCLUSION BODY MYOSITIS; INTERSTITIAL LUNG DISEASE; LEUKEMIA; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIXED CONNECTIVE TISSUE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYELODYSPLASTIC SYNDROME; MYOSITIS; NASOPHARYNX CANCER; PANCREAS CANCER; POLYMYOSITIS; PRIORITY JOURNAL; PROSTATE CANCER; RASH; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SJOEGREN SYNDROME; SKIN CANCER; STANDARDIZED INCIDENCE RATIO; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TESTIS CANCER; AGE; AGED; COMORBIDITY; FACTUAL DATABASE; GENETICS; INCIDENCE; MIDDLE AGED; NEOPLASM; REGISTER; RISK;

ADULT; AGE FACTORS; AGED; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOSITIS; NEOPLASMS; REGISTRIES; RISK; SEX FACTORS; SOUTH AUSTRALIA;

EID: 84880899506     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2489-y     Document Type: Article

References (43)

1. Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85(1): 41-45
2. Buchbinder R, Forbes A, Hall S et al (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 134: 1087-1095
3. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357: 96-100
4. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6: 9-13
5. Dankó K, Ponyi A, Molnar AP, András C, Constantin T (2009) Paraneoplastic myopathy. Curr Opin Rheumatol 21(6): 594-598
6. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E et al (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4): 591-601
7. Levine SM (2006) Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 18(6): 620-624
8. Peng JC, Sheen TS, Hsu MM (1995) Nasopharyngeal carcinoma with dermatomyositis: analysis of 12 cases. Arch Otolaryngol Head Neck Surg 121: 1298-1301
9. Chan HL (1985) Dermatomyositis and cancer in Singapore. Int J Dermatol 24: 447-450
10. Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144: 825-831
11. Airo A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population-based study. J Rheumatol 22: 1300-1303
12. Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326: 363-367
13. Bohan Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7): 344-347
14. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al (1999) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70: 360-374
15. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84(4): 231-249
16. Targoff IN (1993) Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 100:116S-123S
17. Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Bendo R, Briani C et al (2006) Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 39: 217-221
18. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9(4):R78
19. Gunawardena H, Betteridge ZE, McHugh NJ (2008) Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 20(6): 675-680
20. Chinoy H, Fertig N, Oddis CV, Ollier WER, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66: 1345-1349
21. Limaye V, Hakendorf P, Woodman RJ, Blumbergs P, Roberts-Thomson P (2010) Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Int Med J. doi:10.1111/j.1445-5994. 2010.02406.x
22. Trallero-Araguás E, Labrador-Horrillo M, Selva-O'Callaghan A, Martínez MA, Martínez-Gómez X, Palou E et al (2010) Cancerassociated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 89(1): 47-52
23. O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M et al (2006) Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 85(2): 111-127
24. Hohlfeld R (2002) Polymyositis and dermatomyositis. In: Karpati G (ed) Structural and molecular basis of skeletal muscle diseases. ISN Neuropath Press, Switzerland, pp 221-227
25. Dalakas MC (2011) Pathophysiology of inflammatory and autoimmune myopathies. Presse Med 40:e237-e247
26. Chahin N, Engel AG (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70: 418-424
27. Mastaglia FL, Philips VA (2002) Idiopathic inflammatory myopathies, epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am 28: 723-741
28. NE Breslow, NE Day Statistical methods in cancer research: vol II-The design and analysis of cohort studies. IARC Scientific Publications (International Agency for Research on Cancer), pp 49-51
29. Limaye VS, Lester S, Bardy P, Thompson P, Cox S, Blumbergs P, Roberts-Thomson P (2012) A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. Rheumatol Int 32(3): 611-619
30. Buchbinder R, Hill CL (2002) Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 4: 415-426
31. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT (2010) Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 12:R70
32. Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I et al (1998) High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 27: 319-324
33. Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WFC (2009) Malignancy is associated with dermatomyositis but not polymyositis in Northern New England. USA J Rheumatol 36: 2704-2710
34. Zhang W, Jiang SP, Huang L (2009) Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci 13(2): 77-80
35. Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ 3rd (1986) Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 61: 645-653
36. Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P et al (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35: 438-444
37. Barona P, Sierrasesumaga L, Antillon F, Villa-Elizaga I (1993) Study of HLA antigens in patients with osteosarcoma. Hum Hered 43(5): 311-314
38. Abrahamova J, Majsky A, Koutecky J (1981) HLA-antigens in germ cell tumours of various sites. Onkologie 4(1): 19-20
39. Hornmark-Stenstam B, Landberg T, Low B (1978) HLA antigens in Hodgkin's disease of very long survival. Acta Radiol Oncol Radiat Phys Biol 17(4): 283-288
40. Paul SM, Bacharach B, Goepp C (1987) A genetic influence on alveolar cell carcinoma. J Surg Oncol 36(4): 249-252
41. Illeni MT, Pasquali M, La Monica G, Bohm S, Rovini D, Di Re E (1985) HLA antigens in ovarian adenocarcinoma patients. Eur J Gynaecol Oncol 6(2): 121-125
42. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA et al (2002) Southwest oncology group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumour vaccine: impact of HLA Class I antigen expression on outcome. J Clin Oncol 20(8): 2067-2075
43. Luboldt HJ, Kubens BS, Rubben H, Grosse-Wilde H (1996) Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56(4): 826-830